AbbVie Inc (ABBV) — closed signal from April 29, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 28, 2026.
Predicted vs. what happened
ABBV price · publication thesis → realized outcomesplit-adjusted
$195.21 – $202.11Entry zone — fair-value band
$200.91Published — price the day we called it
$225.42Target — the price the thesis aimed for
$266.92Peak — highest point inside the window, not a realized return
$263.20Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 37 days.
Peak price
$266.92
peak on July 28, 2026 — not a realized returnPeak gain
+32.9%
peak, from the publication priceWindow close
$263.20
end-of-window price, context onlyDays to target
37
Window
April 29, 2026 – July 28, 2026
The thesis — published April 29, 2026
Predicted growth
+13%
over the measurement windowTarget price
$225.42
the price the thesis aimed forEntry zone
$195.21 – $202.11
the fair-value band we waited forPrice at publication
$200.91
published April 29, 2026Confidence
68%
how strongly the data lined upTimeframe
Short-term (0–3 months)
AbbVie looks positioned to bounce after a strong quarterly report and higher annual guidance. Sales strength from Skyrizi and Rinvoq helps offset pressure from Humira, and health-care demand tends to hold up in weak markets. However, high debt, weaker recent profit metrics, and ongoing Humira uncertainties limit conviction, and price swings may remain sizable.
Primary drivers
- Quarterly beat and raised guidance shift the short-term story
- Skyrizi and Rinvoq growth offsets Humira-related weakness
- Healthcare demand gives the company defensive support
- Price was oversold, improving the odds of a rebound
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.